Canaccord analyst Richard Close lowered the firm’s price target on Health Catalyst to $11 from $12 and keeps a Buy rating on the shares. The firm said they posted solid 4Q results, though disappointing initial 2024 revenue guide creates reason for pause. With the outlook improving for revenue and adj-EBITDA growth acceleration, they do not believe now is the time to throw in the towel.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst Reports Fourth Quarter and Year End 2023 Results
- Health Catalyst’s Abe Health Registry receives QPP approval
- Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
